In8bio initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of In8bio with a Buy rating and $8 price target. The company has developed gamma-delta T-cell candidates with the initial proof of concept tumor shrinkage in both a solid tumor, glioblastoma, and in a blood tumor, acute myeloid leukemia, the analyst tells investors in a research note. The firm says the therapeutic potential of gamma-delta T-cells is supported by observations over almost three decades demonstrating a significant clinical correlation between high levels of gamma-delta T-cells and better survival outcomes in solid and blood cancers.